Business Description
Dermata Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US2498455045
Total Employee Number:
9Description
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 83.7 | |||||
3-Year EPS without NRI Growth Rate | 84.2 | |||||
3-Year FCF Growth Rate | 83.2 | |||||
3-Year Book Growth Rate | -87.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.35 | |||||
9-Day RSI | 48.63 | |||||
14-Day RSI | 49.64 | |||||
3-1 Month Momentum % | 6.61 | |||||
6-1 Month Momentum % | -50 | |||||
12-1 Month Momentum % | -81.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.09 | |||||
Quick Ratio | 7 | |||||
Cash Ratio | 6.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -710.3 | |||||
Shareholder Yield % | -108.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -120.34 | |||||
ROA % | -95.86 | |||||
ROIC % | -1111.78 | |||||
3-Year ROIIC % | 235.15 | |||||
ROCE % | -124.69 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.78 | |||||
Price-to-Tangible-Book | 0.78 | |||||
EV-to-EBIT | 0.27 | |||||
EV-to-EBITDA | 0.27 | |||||
EV-to-FCF | 0.24 | |||||
| Price-to-Net-Current-Asset-Value | 0.78 | |||||
| Price-to-Net-Cash | 0.85 | |||||
Earnings Yield (Greenblatt) % | 370.37 | |||||
FCF Yield % | -167.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DRMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dermata Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.31 | ||
| Beta | 0.8656 | ||
| 3-Year Sharpe Ratio | -2.75 | ||
| 3-Year Sortino Ratio | -2.27 | ||
| Volatility % | 58.89 | ||
| 14-Day RSI | 49.64 | ||
| 14-Day ATR ($) | 0.099411 | ||
| 20-Day SMA ($) | 1.32 | ||
| 12-1 Month Momentum % | -81.55 | ||
| 52-Week Range ($) | 1.1 - 7.33 | ||
| Shares Outstanding (Mil) | 4.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dermata Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dermata Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 108 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 16 days | ||
| General meeting for 2026 | 2026-05-27 09:00 | 1.23 (-3.91%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.24 (+2.48%) | ||
| Annual report for 2025 | 2026-03-26 | 1.46 (-5.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 1.46 (-5.19%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 3.14 (+0.53%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 6.11 (+0.33%) | ||
| 0.1:1 Stock Split | 2025-08-01 | 6.23 (+4.90%) | ||
| General meeting for 2025 | 2025-07-15 09:00 | 7.29 (+2.53%) |
Show
Entries
Dermata Therapeutics Inc Frequently Asked Questions
What is Dermata Therapeutics Inc(DRMA)'s stock price today?
The current price of DRMA is $1.24. The 52 week high of DRMA is $7.33 and 52 week low is $1.10.
When is next earnings date of Dermata Therapeutics Inc(DRMA)?
The next earnings date of Dermata Therapeutics Inc(DRMA) is 2026-08-13 Est..
Does Dermata Therapeutics Inc(DRMA) pay dividends? If so, how much?
Dermata Therapeutics Inc(DRMA) does not pay dividend.
Guru Commentaries on NAS:DRMA
No articles.
Press Release
Articles on Dermata Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers